The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results
Constantine Tam, MBBS, MD, FRACP, FRCPA from the University of Melbourne, Melbourne, Australia discusses the safety and activity of the BTK inhibitor BGB-3111 plus obinutuzumab in follicular lymphoma and chronic lymphocytic leukemia (CLL) patients (NCT02569476). Prof. Tam explains that BGB-3111 is more specific than ibrutinib. When ibrutinib is combined with an antibody, results are often not as good as expected while BGB-3111 has little off-target selectivity. The Phase Ib study evaluates the combination of BGB-3111 and obinutuzumab and has shown that this combination is well-tolerated. Preliminary results are promising with response rates of approximately 70% and a high complete remission rate (CRR) in follicular lymphoma patients suggesting that this may be one of the most active combinations available for relapsed follicular lymphoma.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.
OncLive News Network On Location: ESMO 2019 Day 1
Gina Columbus recaps on the top news from the 2019 ESMO Congress.
Fitting Zanubrutinib into the Treatment Landscape for Mantle Cell Lymphoma
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the potential role for the next-generation Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) compared to first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma (MCL).
Zanubrutinib is the newest BTK inhibitor to appear in the treatment landscape for patients with MCL, but it does not have significant follow-up time yet, Wang says. There are many interesting points for the role of zanubrutinib in MCL, but Wang adds that this agent is more potent than any other BTK inhibitor currently.
Zanubrutinib is a very positive drug, according to Wang. First- and second-generation BTK inhibitors do not differ significantly in terms of efficacy, but they differ in their toxicity profiles. For example, first-generation BTK inhibitor ibrutinib (Imbruvica) can lead to atrial fibrillation, infection, muscle spasms, infection, and rash in patients with MCL, while acalabrutinib (Calquence), a second-generation drug, has a different toxicity profile. The most common adverse event with acalabrutinib in MCL is headache, Wang notes, which is expected to differ with zanubrutinib.
For more resources and information regarding anticancer targeted therapies in mantle cell lymphoma:
Dr. Zelenetz on Anticipated Research in MCL